Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
Paul M Maciocia, Patrycja A Wawrzyniecka, Brian Philip, Ida Ricciardelli, Ayse U Akarca, Shimobi C Onuoha, Mateusz Legut, David K Cole, Andrew K Sewell, Giuseppe Gritti, Joan Somja, Miguel A Piris, Karl S Peggs, David C Linch, Teresa Marafioti, Martin A Pule
Index: 10.1038/nm.4444
Full Text: HTML
Abstract
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies, Published online: 13 November 2017; doi:10.1038/nm.4444NatureArticleSnippet(type=short-summary, markup= Pule and colleagues identify the TCR β-chain constant region as a new target for chimericantigen receptor (CAR) T cells in treatment of T cell cancers while potentially preserving a healthyT cell repertoire. They demonstrate that anti-TCRB1 CAR T cells eliminate cancerousTCRB1+ T cells while sparing nearly one-third of normal TCRB2+ T cells., isJats=true)
Latest Articles:
Corrigendum: Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury
2018-04-10
[10.1038/nm0418-525b]
Current understanding of the human microbiome
2018-04-10
[10.1038/nm.4517]
Transplanted neural progenitors bridge gaps to benefit cord–injured monkeys
2018-04-10
[10.1038/nm.4531]
2018-04-10
[10.1038/nm.4529]
A new site of attack for a malaria vaccine
2018-04-10
[10.1038/nm.4533]